Calcitite Protect 60 tablets


Categories: ,


Clinical Benefits
  •  Highly bioavailable calcium: Microcrystalline hydroxyapatite is a comprehensive whole bone concentrate consistently showing superior bioavailability over other forms of calcium.1,4 It delivers highly absorbable forms of calcium, phosphorous and bioactive growth factors including transforming growth factor-b, insulin like growth factors, type 1 collagen, glycosaminoglycans and trace minerals to positively impact bone density.5
  • Vitamin D for optimal calcium absorption: Vitamin D is involved in the efficiency of intestinal calcium absorption and also in the parathyroid hormone regulation of serum calcium levels. In a low vitamin D state, the intestine absorbs 10% to 15% of dietary calcium compared to 30% to 40% with adequate vitamin D levels.2 Calcitite Hi-Strength contains 333 IU of vitamin D per tablet to assist calcium absorption and enhance skeletal strength.
  • A meta-analysis of 12 randomised controlled trials has shown 700 IU to 800 IU of vitamin D to enhance skeletal strength. Vitamin D significantly reduced the risk of hip fracture by 26% and non-vertebral fracture by 23%.6 Vitamin D has also been shown to play a role in musculoskeletal function, with vitamin D receptors being identified in human muscle tissue. In a separate, double-blind RCT, 800 IU of vitamin D significantly improved musculoskeletal function, reducing the amount of falls in older patients by 49% over three months.7
  • A two year study involving 60 postmenopausal women evaluated the efficacy of calcium hydroxyapatite (3.32 g/day) and calcium carbonate in the maintenance of optimal bone mineral density. Only calcium hydroxyapatite maintained bone mineral density, while calcium carbonate and the control group showed a significant reduction in bone mineral density (Figure One).3 Similar results have also been demonstrated in a separate study of 40 postmenopausal women. Calcium hydroxyapatite significantly slowed the loss of trabecular bone in comparison to calcium carbonate over 20 months at a dose of 1.4 g calcium/day (Figure Two).1

Figure One: Calcium Hydroxyapatite Reduces Bone Loss.

Castelo-Branco C, Pons F, Vicente JJ, Sanjuan A, Vanrell JA. Preventing postmenopausal bone loss with osseinhydroxyapatite compounds. Results of a two-year, prospective trial. J Reprod Med 1999;44(7):601-5.

Figure Two: Calcium Hydroxapatite Reduces Trabecular Bone Loss.

Ruegsegger P, et al. Comparison of the Treatment Effects of Ossein-Hydroxyapatite Compound and Calcium Carbonate in Osteoporotic Females. Osteoporosis Int (1995) 5:30-34.